{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:07:53Z","timestamp":1788743273762,"version":"build-2803163510"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eururo.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:14:51Z","timestamp":1779311691000},"page":"239-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["From Evidence to Implementation: How Should We Screen for Prostate Cancer in the Modern Era?"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1004-1459","authenticated-orcid":false,"given":"Rouvier","family":"Al-Monajjed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Bratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.05.001_b0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2026.04.005","article-title":"Effect of prostate cancer screening with prostate-specific antigen testing on long-term prostate cancer\u2013specific mortality: a systematic review and meta-analysis of randomized controlled trials","volume":"90","author":"Nguyen","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.001_b0010","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening - 23-year follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.05.001_b0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2025.12.002","article-title":"Risk-adapted prostate cancer screening achieves mammography-like benefits: evidence and implications for Europe","volume":"89","author":"Carlsson","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.001_b0020","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.30474","article-title":"Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years","volume":"123","author":"Pinsky","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.05.001_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071082","article-title":"Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit","volume":"381","author":"Vickers","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.05.001_b0030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2026.05.001_b0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2024.04.030","article-title":"Risk-adjusted screening for prostate cancer-defining the low-risk group by data from the PROBASE trial","volume":"86","author":"Krilaviciute","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.001_b0040","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.05.001_b0045","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.05.001_b0050","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.05.001_b0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2340\/sju.v60.43809","article-title":"Swedish regional population-based organised prostate cancer testing: why, what and how?","volume":"60","author":"Bratt","year":"2025","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2026.05.001_b0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2024.09.003","article-title":"Risk-stratified approach to implementing population-based prostate cancer screening in five pilot sites in the European Union: a protocol for the PRAISE-U project","volume":"70","author":"Chandran","year":"2024","journal-title":"Eur Urol Open Sci"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:26:15Z","timestamp":1788740775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826021585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0302283826021585"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.05.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From Evidence to Implementation: How Should We Screen for Prostate Cancer in the Modern Era?","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}